Clinical Trial 22685

Phase 1/1B, Multicenter, Open-Label, Study of RMC-9805 in Participants with Advanced KRASG12D-Mutant Solid Tumors

Disease Site: Any Site, Esophagus, Liver, Lung, Other Digestive Organ, Pancreas, Small Intestine, Stomach

PI: Kim, Dae Won

Clinical Trial 21790

Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC #783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)

Disease Site: Other Endocrine System

PI: Haider, Mintallah

Clinical Trial 20413

Phase III Study Of Daratumumab/Rhuph20 (Nsc- 810307) + Lenalidomide Or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapy In Patients With Multiple Myeloma (MM) Using Minimal Residual Disease To Direct Therapy Duration (DRAMMATIC STUDY)

Disease Site: Multiple Myeloma

PI: Nishihori, Taiga

Clinical Trial 21858

A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants with Amyloid Light Chain AL Amyloidosis

Disease Site: Multiple Myeloma

PI: Blue, Brandon

Clinical Trial 21899

Phase Ib Expansion Study of CX-5461 in Patients with Solid Tumours and BRCA2 and/or PALB2 Mutation

Disease Site: Breast, Other Female Genital, Ovary, Pancreas, Prostate

PI: Han, Heather

Clinical Trial 21921

A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Fadraciclib (CYC065), an Oral CDK 2/9 Inhibitor, in Subjects with Advanced Solid Tumors and Lymphoma

Disease Site: Breast, Liver, Other Digestive Organ, Other Female Genital, Ovary

PI: Costa, Ricardo

Clinical Trial 22164

A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer (PALOMA-2).

Disease Site: Lung

PI: Saltos, Andreas

Clinical Trial 23135

Disease Site: Multiple Myeloma

PI: Freeman, Ciara

Clinical Trial 19662

Phase II study of stereotactic body radiation therapy and atezolizumab in the management of recurrent, persistent, or metastatic cervical cancer

Disease Site: Cervix

PI: Ahmed, Kamran

Clinical Trial 21551

A Phase 2, Open-Label Randomized Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone vs Carfilzomib, Lenalidomide, and Dexamethasone in Patients with Newly-Diagnosed Multiple Myeloma (ADVANCE)

Disease Site: Multiple Myeloma

PI: Shain, Kenneth

Clinical Trial 21948

A phase 1, open-label, multicentre, safety, pharmacokinetic, pharmacodynamic study of ALX148 in combination with enfortumab vedotin and/or other anticancer therapies in subjects with urothelial carcinoma (ASPEN-07)

Disease Site: Other Urinary

PI: Jain, Rohit

Clinical Trial 22319

A Phase 1B/2 Open-Label Study to Investigate the Safety, Tolerance and Efficacy of Drug Resistant Immunotherapy with Activated, Gene Modified Allogeneic or Autologous gamma delta T Cells (DELTEX) in Combination with Maintenance Temozolomide in Subjects with Recurrent or Newly Diagnosed Glioblastoma

Disease Site: Brain and Nervous System

PI: Liu, James